Aurobindo Pharma gets USFDA approval for its oral suspension

Mumbai, June 5 (UNI) Pharma major Aurobindo Pharma Ltd today announced that it has received the United States Food and Drug Administration (FDA) approval for one of its oral suspension 'Cefpodoxime proxetil' in the strengths of 50mg/5ml and 100mg/5ml.

The antibiotic drug, which is of the third generation, is the sixth cephalosporin approval for the company. With this, the company has representation in each of the first three generations of cephalosporin antibiotics. Cefpodoxime is the generic version of Pharmacia Upjohn's Vantin, the company informed the BSE.

Cefpodoxime is mostly used to treat acute otitis media, community acquired pneumoniae, uncomplicated urinary tract infections and also skin infections.

UNI AR SSS SM1329 to one more of its oral suspension 'Cephalosporins'.

This time it is from its third generation range. Cefpodoxime proxetil for oral suspension in the strengths of 50mg/5ml and 100mg/5ml has been approved. This is the 6th cephalosporin approval for the Company. With this the Company has representation in each of the first three generations of cephalosporin antibiotics.

Cefpodoxime is the generic version of Pharmacia Upjohn's Vantin,the Company said to BSE.

Cefpodoxime is mostly used to treat Acute otitis media, community acquired Pneumoniae, Uncomplicated Urinary tract infections and also skin infections.

UNI